[
  {
    "ts": null,
    "headline": "Moderna (MRNA) Rises But Trails Market: What Investors Should Know",
    "summary": "In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=96720b761a69e7481fa8329edc3982424d6d1afa0479ef3eb5820bf7cd278db6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735944620,
      "headline": "Moderna (MRNA) Rises But Trails Market: What Investors Should Know",
      "id": 132261613,
      "image": "https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=96720b761a69e7481fa8329edc3982424d6d1afa0479ef3eb5820bf7cd278db6"
    }
  },
  {
    "ts": null,
    "headline": "Biden Administration, in its Final Days, Commits More Cash to Bird Flu Preparation",
    "summary": "Biden Administration, in its Final Days, Commits More Cash to Bird Flu Preparation",
    "url": "https://finnhub.io/api/news?id=cba28cdaee93930737a4f05ebfa4f7becc27ee0aaeaaa74687b15a0bee4678c3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735909140,
      "headline": "Biden Administration, in its Final Days, Commits More Cash to Bird Flu Preparation",
      "id": 132537825,
      "image": "",
      "related": "MRNA",
      "source": "MarketWatch",
      "summary": "Biden Administration, in its Final Days, Commits More Cash to Bird Flu Preparation",
      "url": "https://finnhub.io/api/news?id=cba28cdaee93930737a4f05ebfa4f7becc27ee0aaeaaa74687b15a0bee4678c3"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: From Breakthrough COVID-19 Vaccines To Personalized Cancer Therapies",
    "summary": "Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors. See why MRNA stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=ce76b57837faee58c95619bf41c38523478a64b559f1efd0b19d97a17640eb4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735874956,
      "headline": "Moderna: From Breakthrough COVID-19 Vaccines To Personalized Cancer Therapies",
      "id": 132248512,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284796611/image_1284796611.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors. See why MRNA stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=ce76b57837faee58c95619bf41c38523478a64b559f1efd0b19d97a17640eb4b"
    }
  }
]